Evidence map›Paper›PMID 19894180›Full record

ArticleJournal of occupational and environmental hygiene2009

Beryllium alters lipopolysaccharide-mediated intracellular phosphorylation and cytokine release in human peripheral blood mononuclear cells.

Shannon Silva, Kumkum Ganguly, Theresa M Fresquez, Goutam Gupta, T Mark McCleskey, Anu Chaudhary

Abstract read
In one paragraph

Article in Journal of occupational and environmental hygiene, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Chronic beryllium disease: an updated model interaction between innate and acquired immunity.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2011
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shannon SilvaBiosciences Division, Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA.
Kumkum Ganguly
Theresa M Fresquez
Goutam Gupta
T Mark McCleskey
Anu Chaudhary
Los Alamos National Laboratory · USNorthern New Mexico College · US

Funding

UNM COBRE: THEORETICAL STUDY OF SPECIFICITY OF RNA SILENCING MECHANISMP20RR018754 · NCRR · UNIVERSITY OF NEW MEXICO · PI WEARING, HELEN JANE · 2003 to 2011
$16.7M
NCRR NIH HHS P20 RR018754
6 · The paper itself

Abstract

Beryllium exposure in susceptible individuals leads to the development of chronic beryllium disease, a lung disorder marked by release of inflammatory cytokine and granuloma formation. We have previously reported that beryllium induces an immune response even in blood mononuclear cells from healthy individuals. In this study, we investigate the effects of beryllium on lipopolysaccharide-mediated cytokine release in blood mononuclear and dendritic cells from healthy individuals. We found that in vitro treatment of beryllium sulfate inhibits the secretion of lipopolysaccharide-mediated interleukin 10, while the release of interleukin 1beta is enhanced. In addition, not all lipopolysaccharide-mediated responses are altered, as interleukin 6 release in unaffected upon beryllium treatment. Beryllium sulfate-treated cells show altered phosphotyrosine levels upon lipopolysaccharide stimulation. Significantly, beryllium inhibits the phosphorylation of signal transducer and activator of transducer 3, induced by lipopolysaccharide. Finally, inhibitors of phosphoinositide-3 kinase mimic the effects of beryllium in inhibition of interleukin 10 release, while they have no effect on interleukin 1beta secretion. This study strongly suggests that prior exposures to beryllium could alter host immune responses to bacterial infections in healthy individuals, by altering intracellular signaling.

Indexed as

BerylliumCells, CulturedCytokinesEnzyme ActivationEscherichia coliHumansImmunity, InnateInterleukin-10Interleukin-1betaInterleukin-6Leukocytes, MononuclearLipopolysaccharidesPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPhosphorylationSignal TransductionBerylliumberyllium sulfateCytokinesIL10 protein, humanIL1B protein, humanIL6 protein, humanInterleukin-10Interleukin-1betaInterleukin-6LipopolysaccharidesPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsTyrosine

Identifiers

PMID19894180
PMCPMC3607438
OpenAlexW2016038713

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.